- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Boehringer’s nintedanib slows lung function decline in study

Patients who received nintedanib showed a decrease in FVC over 52 weeks. Robina Weermeijer on Unsplash.